CTRI/2013/07/003850
Completed
未知
A prospective pharmacokinetics and dose optimization study of extended infusion of Meropenem in adult critically ill cancer patientsâ??
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tata Memorial Hospital
- Enrollment
- 25
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria
- •Adult critically ill patients
- •Age 18 yr to 70 yrs
- •Known or suspected sepsis.
- •Baseline plasma creatinine concentration within upper limit of normal
- •Meropenem (MEROMER®) therapy initiated in ICU and expected to be continued for at least 3 days
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase I study of optimal dose and pharmacokinetics of a Uracil/Tegafur (UFT) plus oral leucovorin regimen after liver resection for colorectal liver metastasisiver resection for liver metastasis of colorectal cancerJPRN-UMIN000021146Oita university, faculty of medicine, department gastroenterology and pediatric surgery18
Recruiting
Not Applicable
Prediction of the pharmacokinetics and adverse events of nab-paclitaxel in patients with pancreatic cancer by magnetic resonance imagingnresectable locally advanced pancreatic cancer or metastatic pancreatic cancerJPRN-UMIN000026180Juntendo University40
Completed
Not Applicable
Prediction of the pharmacokinetics and adverse events of paritaprevir in patients with hepatitis C virus by magnetic resonance imagingType C chronic hepatitis or type C liver cirrhosisJPRN-UMIN000022587Juntendo University Nerima Hospital Department of Gastroenterology30
Completed
Not Applicable
Prediction of the pharmacokinetics and adverse events of glecaprevir/pibrentasvir in patients with hepatitis C virus by gadoxetic acid enhanced magnetic resonance imagingType C chronic hepatitis or type C liver cirrhosisJPRN-UMIN000034251Juntendo University Nerima Hospital60
Completed
Phase 4
Prospective, pharmacokinetic study for determination of the relationship between lean body weight and anti-Xa activity 4 hours after subcutaneous administration of 5700 IU nadroparin in morbidly obese patients after bariatric surgery.antistolling profylaxe bij bariatrische chirurgiemorbid obesityprofylaxis thrombosisNL-OMON37098Rijnstate Ziekenhuis50